Skip to Main Content

Paper Details

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
Eur Urol Focus
5
2023
Author NameAffiliation
Paul L CrispenUniversity of Florida School of Medicine
Michael A CarducciJohns Hopkins University
  • 1 - 2

Datasets

Release 1.2